

WILPROPHY.

EFFICACY & SAFETY OF WILATE® DURING
PROPHYLAXIS IN PEOPLE WITH ANY TYPE OF VWD

WIL-31 is the largest prospective prophylaxis study in VWD and the only study with a prospective on-demand run-in study as an intra-individual comparator.

WIL-29



6-month on-demand treatment with any plasma-derived VWF/FVIII concentrate

WIL-31


12-month prophylaxis with wilate® 20–40 IU/kg (2–3x per week)

N=33

wilate® prophylaxis led to a reduction in mean total ABR vs on-demand treatment



Total mean ABR were reduced in:



Dosing of wilate® during prophylaxis

Median (range) dose per injection¹



32 (20–45) IU/kg

Median (range) weekly dose (N=33)



58 (28–114) IU/kg

Prophylactic dosing regimen (N=33)



26 patients (79%) required no change in dosing frequency*

Safety during wilate® prophylaxis

ZERO

- Serious AEs related to wilate®
- Thrombotic events

NO

- FVIII accumulation
- Inhibitor development

Sidonio RF Jr et al. Blood Adv 2024; 8:1405–14.

*One patient who had an underlying gastrointestinal condition (relapsing and remitting ulcers in the small bowel) accounted for the majority (35/54) of bleeding events in patients with type 1 VWD in WIL-31. Without this patient, the reduction in total ABR in patients with type 1 VWD was 87%. ABR: annualized bleeding rate; *7 patients switched from 2x to 3x per week during WIL-31 due to > 2 spontaneous BEs or 1 major spontaneous BE within a month; ¹Patients were considered compliant if at least 80% of doses were administered as planned; 1. Octapharma, data on file.

This information is intended for healthcare professionals only. Octapharma medicines are approved in individual countries and regions for specific uses. The licensed indications and other information presented here may vary from the approved use of wilate® in other countries. Please refer to the approved Product Information relevant to your country. wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in children and adults with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes in children 6 years of age and older and adults with VWD. wilate® is also indicated in adolescents and adults with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes, and for on-demand treatment and control of bleeding episodes. Please see the full Prescribing Information at the following link

<https://wilateusa.com/wp-content/uploads/2023/12/wilate-full-prescribing-information.pdf>